A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions

NCT05666518 | Recruiting

• 1 other identifier: 21880
• Study Type: observational
• Target: 1,400
• Locations: 1 country
• Sites: 1

Brief Summary

This is an observational study in which data from Japanese people with chronic heart failure who will be receiving vericiguat is studied. Chronic heart failure (HF) is a long-term condition where the heart does not pump blood as well as it should. Heart failure can lead to other serious medical conditions, and it can lead to hospitalization or death. The drug vericiguat works by increasing the activity of an enzyme called soluble guanylate cyclase (sGC). The sGC enzyme helps regulate the heart and blood circulation. Vericiguat is already available and approved for doctors to prescribe to people who have heart failure. A limited number of patients have been treated with vericiguat. Therefore information about its safety in a broader population and especially among Japanese people as well as for prolonged periods of treatment is still missing. In this study, the researchers want to learn more about how safe vericiguat is if used in Japanese people with long term HF. To see how safe vericiguat is, the researchers will collect the medical problems the participants have during the treatment with vericiguat under real-word conditions. They will particularly focus on the following:

• high blood pressure
• any medical problems due to combination of the study treatment vericiguat with nitrates and nitric oxide (NO) donors or with PDE5 inhibitors
• medical problems in participants with liver problems or with reduced kidney function
• medical problems in participants with low blood pressure below \<100 mmHg or with symptoms due to low blood pressure
• any medical problems after prolonged periods of treatment with vericiguat. These medical problems are also known as "adverse events" (AEs) which may or may not be related to the study treatment. In addition, this study will gather information about how long vericiguat treatment can prevent death caused by cardiovascular problems such as heart attack and stroke compared to standard of care. Cardiovascular death (safety specification) will be assessed in a comparative manner with the control arm as the primary objective The participants will receive their treatments as prescribed by their doctors according to the approved product information. The data for this study will be collected using an electronic case report form (eCRF) and medical records. The following data from the study participants will be documented during visits that take place in routine practice:
• underlying and concomitant diseases,
• prior medication,
• treatment duration,
• laboratory parameters,
• vital signs,
• results of cardiac exams (e.g. cardiac ultrasound),
• heart failure related hospitalization events,
• adverse events. The data collection will start from the beginning of vericiguat/standard of care treatment and will cover a time period of 2 years unless no further information can be expected from the participant at a given point in time, or death. The total study duration will be six years, including data analysis and cleaning.

Conditions

Chronic Heart Failure

Outcome Measures

Primary Outcomes (5)

• Severity of Adverse Events (AEs) for vericiguat arm

  Up to 2 years.

• Seriousness of Adverse Events (AEs) for vericiguat arm

  Up to 2 years

• Outcome of Adverse Events (AEs) for vericiguat arm

  Up to 2 years

• Causality assessment of Adverse Events (AEs) for vericiguat arm

  Up to 2 years

• Incidence of Cardiovascular (CV) death for vericiguat arm and control arm

  Definition of CV death is Heart failure, acute myocardial infarction, stroke (cerebral infarction, cerebral hemorrhage), sudden death, other CV deaths (e.g., pulmonary embolism, peripheral arterial disease), death of unknown cause

  Up to 2 years

Secondary Outcomes (16)

• The duration (days) of vericiguat treatment for vericiguat arm

  Up to 2 years

• The reason for ending vericiguat treatment/observation for vericiguat arm

  Up to 2 years

• Dosage and dose modification of vericiguat treatment for vericiguat arm

  Up to 2 years

• Systolic blood pressure and diastolic blood pressure for vericiguat arm

  Up to 2 years

• Pulse rate for vericiguat arm

  Up to 2 years

Study Arms (2)

vericiguat arm

Japanese patients with a diagnosis of chronic heart failure who received standard treatment and will start vericiguat therapy for chronic heart failure.

Drug: Vericiguat (Verquvo, BAY1021189)

control arm

Japanese patients a diagnosis of chronic heart failure who received standard treatment and will continue standard of care treatment for chronic heart failure.

Drug: Standard of care

Interventions

Vericiguat (Verquvo, BAY1021189) DRUG

Dosage at the discretion of the treating physician, based on the recommendations written in the product information.

vericiguat arm

Standard of care DRUG

Dosage at the discretion of the treating physician

control arm

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population is composed of Japanese patients with chronic heart failure have been prescribed vericiguat or standard treatment by the physician.

You may qualify if:

• vericiguat arm:
• Patients receiving standard treatment for chronic heart failure, and vericiguat will be treated in accordance with the package insert (no history of receiving vericiguat)
• Patients who gave written consent to this investigation
• control arm:
• Patients receiving standard treatment for chronic heart failure according to the package insert of vericiguat as following (no history of receiving vericiguat)
• Prior (within 6 months) heart failure hospitalization or prior (within 3 months) intravenous (IV) diuretics for heart failure not requiring hospitalization (This will be applied only for the first \~75% of patients meeting this criteria to be enrolled.) Note: No more than approximately 25% of patients without a qualifying history of prior heart failure hospitalization within 6 months or prior IV diuretics for heart failure not requiring hospitalization within 3 months can be enrolled in the study.
• New York Heart Association (NYHA) Classification: Class II to Class IV
• Left ventricular ejection fraction (LVEF): less than 45%
• Patients who gave written informed consent to this study

You may not qualify if:

• vericiguat arm:
• \- Patients who are participating in an interventional study
• control arm:
• Patients who have started or are scheduled to start therapy with vericiguat for chronic heart failure
• Patients who are participating in an interventional study

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

Japanese registries

Multiple Locations, Many Locations, Japan

RECRUITING

MeSH Terms

Interventions

vericiguat; Standard of Care

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation

Central Study Contacts

Bayer Clinical Trials Contact

CONTACT

(+)1-888-84 22937; clinical-trials-contact@bayer.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 2, 2022
• First Posted: December 28, 2022
• Study Start: August 31, 2022
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2028
• Last Updated: April 17, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

JP (1)